Schering Takes Aim At Glenmark Over Zetia

Law360, New York (March 29, 2007, 12:00 AM EDT) -- In the latest legal feud over a blockbuster cholesterol drug, Schering-Plough Corp. has hauled Glenmark Pharmaceuticals to court on allegations that the Indian generics maker has infringed a patent covering its anti-cholesterol treatment Zetia.

The lawsuit, filed last Thursday in the U.S. District Court for the District of New Jersey, was brought on behalf of Schering and MSP Singapore Co. LLC, Schering’s exclusive licensee for Zetia.

The complaint accuses the Mumbai-based Glenmark and its United States subsidiary of infringing on U.S. Patent No. RE37,721, which covers...
To view the full article, register now.